Chan Henry Lee Sells 664 Shares of BeOne Medicines (NASDAQ:ONC) Stock

BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) SVP Chan Henry Lee sold 664 shares of the business’s stock in a transaction that occurred on Wednesday, January 7th. The shares were sold at an average price of $331.76, for a total value of $220,288.64. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Chan Henry Lee also recently made the following trade(s):

• On Thursday, December 11th, Chan Henry Lee sold 332 shares of BeOne Medicines stock. The stock was sold at an average price of $325.00, for a total value of $107,900.00.
• On Wednesday, November 12th, Chan Henry Lee sold 996 shares of BeOne Medicines stock. The shares were sold at an average price of $349.17, for a total value of $347,773.32.

BeOne Medicines Stock Performance

Shares of ONC stock opened at $337.89 on Friday. BeOne Medicines Ltd. – Sponsored ADR has a 52 week low of $174.74 and a 52 week high of $385.22. The stock has a market capitalization of $37.05 billion, a PE ratio of 662.53 and a beta of 0.47. The company has a quick ratio of 2.17, a current ratio of 2.39 and a debt-to-equity ratio of 0.03. The firm has a 50 day moving average of $327.96 and a two-hundred day moving average of $313.56.

Analyst Ratings Changes

ONC has been the topic of a number of research analyst reports. Citigroup raised their price objective on shares of BeOne Medicines from $399.00 to $405.00 and gave the stock a “buy” rating in a report on Monday, November 10th. Jefferies Financial Group reaffirmed a “buy” rating and issued a $420.00 target price on shares of BeOne Medicines in a research report on Monday, November 17th. Weiss Ratings reissued a “sell (d-)” rating on shares of BeOne Medicines in a research report on Wednesday, October 8th. Zacks Research lowered BeOne Medicines from a “strong-buy” rating to a “hold” rating in a report on Tuesday, October 28th. Finally, JPMorgan Chase & Co. lifted their target price on BeOne Medicines from $345.00 to $385.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 8th. Twelve equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $367.36.

Institutional Trading of BeOne Medicines

Several institutional investors and hedge funds have recently added to or reduced their stakes in ONC. Primecap Management Co. CA acquired a new stake in BeOne Medicines during the 2nd quarter worth approximately $1,231,720,000. Temasek Holdings Private Ltd purchased a new stake in shares of BeOne Medicines during the second quarter worth approximately $244,603,000. Marshall Wace LLP acquired a new stake in shares of BeOne Medicines during the second quarter worth $113,190,000. Baird Financial Group Inc. acquired a new stake in shares of BeOne Medicines during the second quarter worth $82,895,000. Finally, Connor Clark & Lunn Investment Management Ltd. purchased a new position in BeOne Medicines in the 2nd quarter valued at $73,347,000. 48.55% of the stock is owned by hedge funds and other institutional investors.

About BeOne Medicines

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.